查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1641752

全球鼻腔給藥裝置市場（按系統、容器和應用）- 機會分析和產業預測（2024-2033 年）

Intranasal Drug Delivery Devices Market By System , By Container By Application : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 260 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2023 年全球鼻腔給藥裝置市場規模價值為 17 億美元，預計到 2033 年將達到 38 億美元，2024 年至 2033 年的複合年成長率為 8.7%。

鼻腔內給藥設備市場-IMG1

鼻腔給藥裝置是用於透過鼻腔給藥治療藥物的醫療設備。這種給藥途徑提供了一種非侵入性且有效的方法，可以將藥物直接輸送到全身循環或靶向中樞神經系統，繞過胃腸道和肝臟的首過代謝。鼻用裝置通常包括鼻用噴霧器、霧化器和粉末分配器，用於增強藥物在鼻黏膜的吸收。

全球鼻腔給藥設備市場的成長是由呼吸道疾病、過敏、偏頭痛以及癲癇和鴉片類藥物過量攝取等需要快速用藥的疾病盛行率的驚人上升所推動的。根據公共衛生研究機構衛生指標與評估研究所發布的研究報告，2019年，慢性呼吸道疾病導致400萬人死亡，罹病人數達4.546億，排名第三。此外，患者對非侵入性藥物傳遞方法的需求激增，推動了鼻腔裝置在慢性和急性疾病中的應用。此外，鼻腔給藥可有效地針對中樞神經系統，因為它允許藥物繞過血腦障壁。這促進了阿茲海默症和帕金森氏症等神經系統疾病的治療研究。此外，家庭保健和自我治療的興起趨勢推動了對易於使用的藥物輸送系統（包括鼻用裝置）的需求，從而極大地推動了市場成長。然而，頻繁使用鼻用設備會對鼻黏膜造成刺激、乾燥和其他不適，從而限制了其應用並阻礙了市場成長。此外，由於穩定性問題或鼻黏膜滲透性差，並非所有藥物都適合經鼻給藥，這限制了這些裝置的應用範圍。同時，滴鼻劑和無針裝置等創新正在提高藥物輸送的精確度和便利性。用於劑量追蹤的整合感測器的智慧型設備也正在湧現，提高了患者對藥物的依從性。預計這些發展將為預測期內全球市場的擴張提供有利可圖的機會。

鼻腔給藥裝置產業分為系統、容器、應用和地區。根據系統，市場分為定量系統、多劑量系統和單位劑量系統。依容器類型分為非壓力容器和壓力容器。依用途可分為慢性阻塞性肺病（COPD）、鼻炎、囊腫纖維化、鼻塞、氣喘等。按地區分析，市場涵蓋北美、歐洲、亞太地區、拉丁美洲、中東和非洲。

主要發現

根據系統，多劑量系統部分預計將在 2024-2033 年期間佔據市場主導地位。

根據船舶類型，非加壓系統船舶部分預計在預測期內呈現最高成長。

根據應用，預計氣喘領域在不久的將來將以驚人的速度成長。

根據地區，預計北美將在 2023 年佔據鼻腔給藥裝置市場最大的市場佔有率，並預計在預測期內佔據市場主導地位。

本報告可提供客製化（請聯絡銷售人員以了解其他費用和時間表）

  • 根據客戶興趣加入公司簡介
  • 歷史市場資料
  • 導入/匯出分析/資料

目錄

第 1 章 簡介

第 2 章執行摘要

第3章 市場狀況

  • 市場定義和範圍
  • 主要發現
    • 主要投資機會
    • 關鍵成功策略
  • 波特五力分析
  • 市場動態
    • 驅動程式
    • 限制因素
    • 機會

第4章。

  • 市場概況
  • 固定劑量
  • 多劑量系統
  • 單位劑量系統

第5章 鼻腔給藥裝置市場（依容器分類）

  • 市場概況
  • 非加壓容器
  • 壓力容器

第6章 鼻腔給藥裝置市場（依應用）

  • 市場概況
  • 慢性阻塞性肺病
  • 鼻炎
  • 囊腫纖維化
  • 鼻塞
  • 氣喘
  • 其他

7. 鼻腔給藥裝置市場（按地區）

  • 市場概況
  • 北美洲
    • 主要市場趨勢和機遇
    • 美國鼻腔給藥裝置市場
    • 加拿大鼻腔給藥裝置市場
    • 墨西哥鼻腔給藥裝置市場
  • 歐洲
    • 主要市場趨勢和機遇
    • 法國鼻腔給藥裝置市場
    • 德國鼻腔給藥裝置市場
    • 義大利鼻腔給藥裝置市場
    • 西班牙鼻腔給藥裝置市場
    • 英國鼻腔給藥裝置市場
    • 其他歐洲國家鼻腔給藥裝置市場
  • 亞太地區
    • 主要市場趨勢和機遇
    • 中國鼻腔給藥裝置市場
    • 日本鼻腔給藥裝置市場
    • 印度鼻腔給藥設備市場
    • 韓國鼻腔給藥裝置市場
    • 澳洲鼻腔給藥裝置市場
    • 其他亞太地區鼻腔給藥裝置市場
  • 拉丁美洲、中東和非洲
    • 主要市場趨勢和機遇
    • 巴西鼻腔給藥裝置市場
    • 南非鼻腔給藥裝置市場
    • 沙烏地阿拉伯的鼻腔給藥裝置市場
    • 其他拉丁美洲、中東和非洲鼻腔給藥裝置市場

第8章 競爭格局

  • 介紹
  • 關鍵成功策略
  • 前 10 家公司的產品映射
  • 競爭儀錶板
  • 競爭熱圖
  • 主要企業的定位：2023年

第9章 公司簡介

  • AptarGroup, Inc.
  • Teleflex Incorporated
  • Nemera
  • Becton, Dickinson And Company
  • OptiNose, Inc.
  • GlaxoSmithKline Plc.
  • AstraZeneca
  • Kurve Technology, Inc.
  • Johnson And Johnson
  • Merck And Co., Inc.
簡介目錄
Product Code: A324453

The intranasal drug delivery devices market was valued at $1.7 billion in 2023, and is projected to reach $3.8 billion by 2033, growing at a CAGR of 8.7% from 2024 to 2033.

Intranasal Drug Delivery Devices Market - IMG1

Intranasal drug delivery devices are medical devices designed to administer therapeutic agents through the nasal cavity. This route of administration provides a non-invasive and efficient means to deliver drugs directly into the systemic circulation or target the central nervous system, bypassing the gastrointestinal tract and first-pass metabolism in the liver. Intranasal devices commonly include nasal sprays, nebulizers, and powder dispensers, tailored to enhance drug absorption through the nasal mucosa.

The growth of the global intranasal drug delivery devices market is driven by alarming increase in prevalence of respiratory diseases, allergies, migraines as well as conditions requiring rapid drug action, such as epilepsy and opioid overdose. According to a study published by the Institute for Health Metrics and Evaluation-a public health research institute-chronic respiratory diseases were responsible for 4.0 million deaths with a prevalence of 454.6 million cases in 2019, ranking as the third leading cause of death. In addition, surge in demand for non-invasive drug delivery methods among patients is boosting the adoption of intranasal devices for both chronic and acute conditions. Moreover, intranasal drug delivery is effective in targeting the central nervous system, as it allows drugs to bypass the blood-brain barrier. This is fostering research into treatments for neurological disorders, such as Alzheimer's and Parkinson's disease. Furthermore, rise of home healthcare and self-medication trends is driving the demand for easy-to-use drug delivery systems, including intranasal devices, which significantly fosters the market growth. However, frequent use of intranasal devices may cause irritation, dryness, or other discomfort in the nasal mucosa, which limits their adoption, thereby hampering the market growth. In addition, not all drugs are suitable for intranasal delivery due to stability issues or low permeability through the nasal mucosa, which restricts the range of applications for these devices. On the contrary, innovations such as metered-dose nasal sprays and needle-free devices improve drug delivery precision and user-friendliness. Smart devices integrated with sensors for dose tracking are also emerging, enhancing patient adherence. Such developments are expected to offer remunerative opportunities for the expansion of the global market during the forecast.

The intranasal drug delivery devices industry is segmented into system, container, application, and region. By system, the market is segregated into metered dose, multi-dose systems, and unit-dose systems. On the basis of containers, it is bifurcated into non-pressurized containers and pressurized containers. Depending on application, it is divided into chronic obstructive pulmonary disease (COPD) , rhinitis, cystic fibrosis, nasal congestion, asthma, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By system, the multi-dose systems segment is expected to dominate the market from 2024 to 2033.

On the basis of container, the non-pressurized system containers segment is anticipated to exhibit the highest growth during the forecast period.

Depending on application, the asthma segment is projected to grow at a notable pace in the near future.

Region wise, North America held the largest market share in the intranasal drug delivery devices market in 2023, and is expected to dominate the market during the forecast period.

Competition Analysis

Competitive analysis and profiles of the major players in the global intranasal drug delivery devices market include AptarGroup, Inc., Teleflex Incorporated, Nemera, Becton, Dickinson and Company, OptiNose, Inc., GlaxoSmithKline Plc., AstraZeneca, Kurve Technology, Inc., Johnson & Johnson, and Merck & Co., Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain a strong foothold in the global market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Additional company profiles with specific to client's interest
  • Historic market data
  • Import Export Analysis/Data

Key Market Segments

By System

  • Metered Dose
  • Multi-Dose Systems
  • Unit-Dose Systems

By Container

  • Non-Pressurized Containers
  • Pressurized Containers

By Application

  • Chronic Obstructive Pulmonary Disease
  • Rhinitis
  • Cystic Fibrosis
  • Nasal Congestion
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • Italy
    • Spain
    • UK
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA

Key Market Players:

    • AptarGroup, Inc.
    • Teleflex Incorporated
    • nemera
    • Becton, Dickinson and Company
    • OptiNose, Inc.
    • GlaxoSmithKline plc.
    • AstraZeneca
    • Kurve Technology, Inc.
    • Johnson & Johnson
    • Merck & Co., Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: INTRANASAL DRUG DELIVERY DEVICES MARKET, BY SYSTEM

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By System
  • 4.2. Metered Dose
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Multi-Dose Systems
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Unit-Dose Systems
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country

CHAPTER 5: INTRANASAL DRUG DELIVERY DEVICES MARKET, BY CONTAINER

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Container
  • 5.2. Non-Pressurized Containers
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Pressurized Containers
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country

CHAPTER 6: INTRANASAL DRUG DELIVERY DEVICES MARKET, BY APPLICATION

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Application
  • 6.2. Chronic Obstructive Pulmonary Disease
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Rhinitis
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Cystic Fibrosis
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country
  • 6.5. Nasal Congestion
    • 6.5.1. Key Market Trends, Growth Factors and Opportunities
    • 6.5.2. Market Size and Forecast, By Region
    • 6.5.3. Market Share Analysis, By Country
  • 6.6. Others
    • 6.6.1. Key Market Trends, Growth Factors and Opportunities
    • 6.6.2. Market Size and Forecast, By Region
    • 6.6.3. Market Share Analysis, By Country

CHAPTER 7: INTRANASAL DRUG DELIVERY DEVICES MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By System
    • 7.2.3. Market Size and Forecast, By Container
    • 7.2.4. Market Size and Forecast, By Application
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Intranasal Drug Delivery Devices Market
      • 7.2.6.1. Market Size and Forecast, By System
      • 7.2.6.2. Market Size and Forecast, By Container
      • 7.2.6.3. Market Size and Forecast, By Application
    • 7.2.7. Canada Intranasal Drug Delivery Devices Market
      • 7.2.7.1. Market Size and Forecast, By System
      • 7.2.7.2. Market Size and Forecast, By Container
      • 7.2.7.3. Market Size and Forecast, By Application
    • 7.2.8. Mexico Intranasal Drug Delivery Devices Market
      • 7.2.8.1. Market Size and Forecast, By System
      • 7.2.8.2. Market Size and Forecast, By Container
      • 7.2.8.3. Market Size and Forecast, By Application
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By System
    • 7.3.3. Market Size and Forecast, By Container
    • 7.3.4. Market Size and Forecast, By Application
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. France Intranasal Drug Delivery Devices Market
      • 7.3.6.1. Market Size and Forecast, By System
      • 7.3.6.2. Market Size and Forecast, By Container
      • 7.3.6.3. Market Size and Forecast, By Application
    • 7.3.7. Germany Intranasal Drug Delivery Devices Market
      • 7.3.7.1. Market Size and Forecast, By System
      • 7.3.7.2. Market Size and Forecast, By Container
      • 7.3.7.3. Market Size and Forecast, By Application
    • 7.3.8. Italy Intranasal Drug Delivery Devices Market
      • 7.3.8.1. Market Size and Forecast, By System
      • 7.3.8.2. Market Size and Forecast, By Container
      • 7.3.8.3. Market Size and Forecast, By Application
    • 7.3.9. Spain Intranasal Drug Delivery Devices Market
      • 7.3.9.1. Market Size and Forecast, By System
      • 7.3.9.2. Market Size and Forecast, By Container
      • 7.3.9.3. Market Size and Forecast, By Application
    • 7.3.10. UK Intranasal Drug Delivery Devices Market
      • 7.3.10.1. Market Size and Forecast, By System
      • 7.3.10.2. Market Size and Forecast, By Container
      • 7.3.10.3. Market Size and Forecast, By Application
    • 7.3.11. Rest Of Europe Intranasal Drug Delivery Devices Market
      • 7.3.11.1. Market Size and Forecast, By System
      • 7.3.11.2. Market Size and Forecast, By Container
      • 7.3.11.3. Market Size and Forecast, By Application
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By System
    • 7.4.3. Market Size and Forecast, By Container
    • 7.4.4. Market Size and Forecast, By Application
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. China Intranasal Drug Delivery Devices Market
      • 7.4.6.1. Market Size and Forecast, By System
      • 7.4.6.2. Market Size and Forecast, By Container
      • 7.4.6.3. Market Size and Forecast, By Application
    • 7.4.7. Japan Intranasal Drug Delivery Devices Market
      • 7.4.7.1. Market Size and Forecast, By System
      • 7.4.7.2. Market Size and Forecast, By Container
      • 7.4.7.3. Market Size and Forecast, By Application
    • 7.4.8. India Intranasal Drug Delivery Devices Market
      • 7.4.8.1. Market Size and Forecast, By System
      • 7.4.8.2. Market Size and Forecast, By Container
      • 7.4.8.3. Market Size and Forecast, By Application
    • 7.4.9. South Korea Intranasal Drug Delivery Devices Market
      • 7.4.9.1. Market Size and Forecast, By System
      • 7.4.9.2. Market Size and Forecast, By Container
      • 7.4.9.3. Market Size and Forecast, By Application
    • 7.4.10. Australia Intranasal Drug Delivery Devices Market
      • 7.4.10.1. Market Size and Forecast, By System
      • 7.4.10.2. Market Size and Forecast, By Container
      • 7.4.10.3. Market Size and Forecast, By Application
    • 7.4.11. Rest of Asia-Pacific Intranasal Drug Delivery Devices Market
      • 7.4.11.1. Market Size and Forecast, By System
      • 7.4.11.2. Market Size and Forecast, By Container
      • 7.4.11.3. Market Size and Forecast, By Application
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By System
    • 7.5.3. Market Size and Forecast, By Container
    • 7.5.4. Market Size and Forecast, By Application
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Intranasal Drug Delivery Devices Market
      • 7.5.6.1. Market Size and Forecast, By System
      • 7.5.6.2. Market Size and Forecast, By Container
      • 7.5.6.3. Market Size and Forecast, By Application
    • 7.5.7. South Africa Intranasal Drug Delivery Devices Market
      • 7.5.7.1. Market Size and Forecast, By System
      • 7.5.7.2. Market Size and Forecast, By Container
      • 7.5.7.3. Market Size and Forecast, By Application
    • 7.5.8. Saudi Arabia Intranasal Drug Delivery Devices Market
      • 7.5.8.1. Market Size and Forecast, By System
      • 7.5.8.2. Market Size and Forecast, By Container
      • 7.5.8.3. Market Size and Forecast, By Application
    • 7.5.9. Rest of LAMEA Intranasal Drug Delivery Devices Market
      • 7.5.9.1. Market Size and Forecast, By System
      • 7.5.9.2. Market Size and Forecast, By Container
      • 7.5.9.3. Market Size and Forecast, By Application

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top Winning Strategies
  • 8.3. Product Mapping Of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. AptarGroup, Inc.
    • 9.1.1. Company Overview
    • 9.1.2. Key Executives
    • 9.1.3. Company Snapshot
    • 9.1.4. Operating Business Segments
    • 9.1.5. Product Portfolio
    • 9.1.6. Business Performance
    • 9.1.7. Key Strategic Moves and Developments
  • 9.2. Teleflex Incorporated
    • 9.2.1. Company Overview
    • 9.2.2. Key Executives
    • 9.2.3. Company Snapshot
    • 9.2.4. Operating Business Segments
    • 9.2.5. Product Portfolio
    • 9.2.6. Business Performance
    • 9.2.7. Key Strategic Moves and Developments
  • 9.3. Nemera
    • 9.3.1. Company Overview
    • 9.3.2. Key Executives
    • 9.3.3. Company Snapshot
    • 9.3.4. Operating Business Segments
    • 9.3.5. Product Portfolio
    • 9.3.6. Business Performance
    • 9.3.7. Key Strategic Moves and Developments
  • 9.4. Becton, Dickinson And Company
    • 9.4.1. Company Overview
    • 9.4.2. Key Executives
    • 9.4.3. Company Snapshot
    • 9.4.4. Operating Business Segments
    • 9.4.5. Product Portfolio
    • 9.4.6. Business Performance
    • 9.4.7. Key Strategic Moves and Developments
  • 9.5. OptiNose, Inc.
    • 9.5.1. Company Overview
    • 9.5.2. Key Executives
    • 9.5.3. Company Snapshot
    • 9.5.4. Operating Business Segments
    • 9.5.5. Product Portfolio
    • 9.5.6. Business Performance
    • 9.5.7. Key Strategic Moves and Developments
  • 9.6. GlaxoSmithKline Plc.
    • 9.6.1. Company Overview
    • 9.6.2. Key Executives
    • 9.6.3. Company Snapshot
    • 9.6.4. Operating Business Segments
    • 9.6.5. Product Portfolio
    • 9.6.6. Business Performance
    • 9.6.7. Key Strategic Moves and Developments
  • 9.7. AstraZeneca
    • 9.7.1. Company Overview
    • 9.7.2. Key Executives
    • 9.7.3. Company Snapshot
    • 9.7.4. Operating Business Segments
    • 9.7.5. Product Portfolio
    • 9.7.6. Business Performance
    • 9.7.7. Key Strategic Moves and Developments
  • 9.8. Kurve Technology, Inc.
    • 9.8.1. Company Overview
    • 9.8.2. Key Executives
    • 9.8.3. Company Snapshot
    • 9.8.4. Operating Business Segments
    • 9.8.5. Product Portfolio
    • 9.8.6. Business Performance
    • 9.8.7. Key Strategic Moves and Developments
  • 9.9. Johnson And Johnson
    • 9.9.1. Company Overview
    • 9.9.2. Key Executives
    • 9.9.3. Company Snapshot
    • 9.9.4. Operating Business Segments
    • 9.9.5. Product Portfolio
    • 9.9.6. Business Performance
    • 9.9.7. Key Strategic Moves and Developments
  • 9.10. Merck And Co., Inc.
    • 9.10.1. Company Overview
    • 9.10.2. Key Executives
    • 9.10.3. Company Snapshot
    • 9.10.4. Operating Business Segments
    • 9.10.5. Product Portfolio
    • 9.10.6. Business Performance
    • 9.10.7. Key Strategic Moves and Developments